

## HeLa/GFP Cell Line

**CATALOG NUMBER:** AKR-213


**STORAGE:** Liquid nitrogen

*Note: For best results begin culture of cells immediately upon receipt. If this is not possible, store at -80°C until first culture. Store subsequent cultured cells long term in liquid nitrogen.*

**QUANTITY & CONCENTRATION:** 1 mL,  $1 \times 10^6$  cells/mL in 70% DMEM, 20% FBS, 10% DMSO

### Background

HeLa cells are the most widely used cancer cell lines in the world. These cells were taken from a lady called Henrietta Lacks from her cancerous cervical tumor in 1951 which today is known as the HeLa cells. These were the very first cell lines to survive outside the human body and grow. Both GFP and blasticidin-resistant genes are introduced into parental HeLa cells using lentivirus.



**Figure 1.** HeLa/GFP Cell Line. Left: GFP Fluorescence; Right: Phase Contrast.

### Quality Control

This cryovial contains at least  $1.0 \times 10^6$  HeLa/GFP cells as determined by morphology, trypan-blue dye exclusion, and viable cell count. The HeLa/GFP cells are tested free of microbial contamination.

### Medium

1. Culture Medium: D-MEM (high glucose), 10% fetal bovine serum (FBS), 0.1 mM MEM Non-Essential Amino Acids (NEAA), 2 mM L-glutamine, 1% Pen-Strep, (optional) 10  $\mu$ g/mL Blasticidin.
2. Freeze Medium: 70% DMEM, 20% FBS, 10% DMSO.

### Methods

#### Establishing HeLa/GFP Cultures from Frozen Cells

1. Place 10 mL of complete DMEM growth medium in a 50-mL conical tube. Thaw the frozen cryovial of cells within 1–2 minutes by gentle agitation in a 37°C water bath. Decontaminate the cryovial by wiping the surface of the vial with 70% (v/v) ethanol.
2. Transfer the thawed cell suspension to the conical tube containing 10 ml of growth medium.
3. Collect the cells by centrifugation at 1000 rpm for 5 minutes at room temperature. Remove the growth medium by aspiration.
4. Resuspend the cells in the conical tube in 15 mL of fresh growth medium by gently pipetting up and down.
5. Transfer the 15 mL of cell suspension to a T-75 tissue culture flask. Place the cells in a 37°C incubator at 5% CO<sub>2</sub>.
6. Monitor cell density daily. Cells should be passaged when the culture reaches 95% confluence.

### **Recent Product Citations**

1. Marschhofer, M. et al. (2026). Optimized lipid nanoparticles for pulmonary delivery of CRISPR/Cas9 targeting KRAS G12S in lung cancer. *J Control Release*. **391**:114607. doi: 10.1016/j.jconrel.2026.114607.
2. Dondi, C. et al. (2025). A self-assembled protein  $\beta$ -helix as a self-contained biofunctional motif. *Nat Commun*. **16**(1):4535. doi: 10.1038/s41467-025-59873-1.
3. Yang, X. et al. (2025). 3D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor Perhexiline. *Adv Healthc Mater*. doi: 10.1002/adhm.202404072.
4. Sun, Q. et al. (2024). Versatile Mechanically Tunable Hydrogels for Therapeutic Delivery Applications. *Adv Healthc Mater*. **13**(18):e2304287. doi: 10.1002/adhm.202304287.
5. García-Acevedo, P. et al. (2024). Simple thermal treatment to improve the MRI and magnetic hyperthermia performance of hybrid iron Oxide-Mesoporous silica nanocarriers. *J Mol Liq*. doi: 10.1016/j.molliq.2024.124299.
6. Arellano, L. G. et al. (2023). Light excitation of gold Nanorod-Based hybrid nanoplatforms for simultaneous bimodal phototherapy. *J. Mol. Liq*. doi: 10.1016/j.molliq.2023.121511.
7. Sánchez-Arribas, N. et al. (2020). Protein Expression Knockdown in Cancer Cells Induced by a Gemini Cationic Lipid Nanovector with Histidine-Based Polar Heads. *Pharmaceutics*. **12**(9):E791. doi: 10.3390/pharmaceutics12090791.
8. Villar-Alvarez, E. et al. (2019). Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules. *J Nanobiotechnology*. **17**(1):106. doi: 10.1186/s12951-019-0538-3.
9. Cunningham, A.J. et al. (2020). Cholic acid-based mixed micelles as siRNA delivery agents for gene therapy. *Int J Pharm*. doi: 10.1016/j.ijpharm.2020.119078.
10. Kawaguchi, T. et al. (2019). Changes to the TDP-43 and FUS Interactomes Induced by DNA Damage. *J Proteome Res*. doi: 10.1021/acs.jproteome.9b00575.
11. Bovone, G. et al. (2019). Flow-based reactor design for the continuous production of polymeric nanoparticles. *AIChE J*. doi:10.1002/aic.16840.
12. Bertsch, P. et al. (2019). Injectable Biocompatible Hydrogels from Cellulose Nanocrystals for Locally Targeted Sustained Drug Release. *ACS Appl Mater Interfaces*. doi: 10.1021/acsami.9b15896.
13. Villar-Alvarez, E. et al. (2019). siRNA Silencing by Chemically Modified Biopolymeric Nanovectors. *ACS Omega*. **4**(2):3904-3921. doi:10.1021/acsomega.8b02875.

14. Encinas-Basurto, D. et al. (2018). Hybrid folic acid-conjugated gold nanorods-loaded human serum albumin nanoparticles for simultaneous photothermal and chemotherapeutic therapy. *Mater Sci Eng C Mater Biol Appl.* **91**:669-678. doi: 10.1016/j.msec.2018.06.002.
15. Pikabea, A. et al. (2018). pH-controlled doxorubicin delivery from PDEAEMA-based nanogels. *Journal of Molecular Liquids.* **266**:321-329. doi:10.1016/j.molliq.2018.06.068.
16. Cambón, A. et al. (2018). Characterization of the complexation phenomenon and biological activity in vitro of polyplexes based on Tetronic T901 and DNA. *J Colloid Interface Sci.* **519**:58-70. doi: 10.1016/j.jcis.2018.02.051.
17. Lin, Y. et al. (2018). Activatable cell-biomaterial interfacing with photo-caged peptides. *Chem Sci.* **10**(4):1158-1167. doi: 10.1039/c8sc04725a.
18. Wu, C. et al. (2018). Rationally Designed Polycationic Carriers for Potent Polymeric siRNA-Mediated Gene Silencing. *ACS Nano.* **12**(7):6504-6514. doi: 10.1021/acsnano.7b08777.
19. Giampietro, C. et al. (2017). Cholesterol impairment contributes to neuroserpin aggregation. *Sci Rep.* **7**:43669. doi: 10.1038/srep43669.
20. Ganini, D. et al. (2017). Fluorescent proteins such as eGFP lead to catalytic oxidative stress in cells. *Redox Biol.* **12**:462-468. doi: 10.1016/j.redox.2017.03.002.
21. Du, X. et al. (2017). In situ generated D-peptidic nanofibrils as multifaceted apoptotic inducers to target cancer cells. *Cell Death Dis.* **8**(2):e2614. doi: 10.1038/cddis.2016.466.
22. Li, G. et al., (2017). Patching of Lipid Rafts by Molecular Self-Assembled Nanofibrils Suppresses Cancer Cell Migration. *Chem.* **2**(2):283–298. doi: 10.1016/j.chempr.2017.01.002.
23. Chen, X. et al. (2016). Patterned poly (dopamine) films for enhanced cell adhesion. *Bioconj. Chem.* doi:10.1021/acs.bioconjchem.6b00544.
24. Castleberry, S. A. et al. (2016). Nanolayered siRNA delivery platforms for local silencing of CTGF reduce cutaneous scar contraction in third-degree burns. *Biomaterials.* doi:10.1016/j.biomaterials.2016.04.007.
25. Alidori, S. et al. (2016). Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. *Sci Transl Med.* doi:10.1126/scitranslmed.aac9647.
26. Shopsowitz, K. E. et al. (2015). Periodic-shRNA molecules are capable of gene silencing, cytotoxicity and innate immune activation in cancer cells. *Nucleic Acids Res.* doi:10.1093/nar/gkv1488.
27. Castleberry, S. A. et al. (2015). Self-assembled wound dressings silence MMP-9 and improve diabetic wound healing in vivo. *Adv Mater.* doi:10.1002/adma.201503565.
28. Dosta, P. et al. (2015). Surface charge tunability as a powerful strategy to control electrostatic interaction for high efficiency silencing, using tailored oligopeptide-modified Poly (beta-amino ester) s (PBAEs). *Acta Biomater.* doi: 10.1016/j.actbio.2015.03.029.
29. Topete, A. et al. (2014). NIR-light active hybrid nanoparticles for combined imaging and bimodal therapy of cancerous cells. *J Mater Chem.* **2**:6967-6977.
30. Weerakkody, D. et al. (2013). Family of pH (low) Insertion Peptides for Tumor Targeting. *PNAS.* **110**:5834-5839.

## **Warranty**

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS's sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

*This product is for RESEARCH USE ONLY; not for use in diagnostic procedures.*

**Contact Information**

Cell Biolabs, Inc.  
5628 Copley Drive  
San Diego, CA 92111  
Worldwide: +1 858-271-6500  
USA Toll-Free: 1-888-CBL-0505  
E-mail: [tech@cellbiolabs.com](mailto:tech@cellbiolabs.com)  
[www.cellbiolabs.com](http://www.cellbiolabs.com)

©2010-2026: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.